Ray Therapeutics Stock
| Valuation | $383.58M1 |
| Valuation Date | Apr 21, 2026 |
| Implied Valuation | n/a |
| Last Price | n/a |
| 52-Week High | n/a |
| 52-Week Low | n/a |
| YTD Return | n/a |
| 1-Year Return | n/a |
| 3-Year Return | n/a |
| Total Funding | $230.95M2 |
| Latest Round Amount | $125M3 |
| Latest Round | Series B |
| Funding Rounds | 3 |
| IPO Status | Unknown |
| Expected IPO Date | n/a |
| Revenue | n/a |
| Revenue Type | n/a |
| P/S Ratio | n/a |
About Ray Therapeutics
Ray Therapeutics is a clinical-stage biotechnology company developing optogenetic gene therapies that aim to restore vision in people with degenerative retinal diseases. Its approach uses a single intravitreal injection to deliver a bioengineered light-sensitive protein into surviving retinal neurons, turning those cells into new photoreceptors so the retina can again send visual signals to the brain regardless of the underlying genetic mutation. The lead program, RTx-015, is in clinical development for retinitis pigmentosa, while a second program, RTx-021, targets macular diseases such as Stargardt disease and geographic atrophy. Ray Therapeutics has no approved products yet and makes money by raising venture capital to fund its pipeline, with the aim of earning revenue from these therapies once they reach the market. The company was founded in 2021 by Paul Bresge and Sean Ainsworth and is headquartered in Berkeley, California.
Invest in Ray Therapeutics
Ray Therapeutics is a private company, so you can't purchase it with a regular brokerage account. However, the company is listed on Forge.
Forge is a trusted platform for transactions of shares of private companies. It is a subsidiary of The Charles Schwab Corporation.
Invest on ForgeDisclosure: Stock Analysis may be compensated for user sign-ups through Forge links.
News
Ray Therapeutics Granted Priority Medicines (PRIME) Designation from the European Medicines Agency for RTx-015 in Retinitis Pigmentosa
BERKELEY, Calif.--(BUSINESS WIRE)--Ray Therapeutics (RayTx), an industry-leading clinical-stage biopharmaceutical company pioneering differentiated vision restoration therapies for those living with s...
Ray Therapeutics Announces Upsized and Oversubscribed $125 Million Series B Financing for Vision Restoration Treatments
Ray Therapeutics closed a $125 million Series B led by Janus Henderson Investors to advance late-stage development of its lead optogenetic gene therapy RTx-015 for retinitis pigmentosa.
Ray Therapeutics Announces $125 Million Series B Financing
Ray Therapeutics closed an oversubscribed $125 million Series B led by Janus Henderson Investors to advance its vision restoration gene therapy programs RTx-015 and RTx-021.
Ray Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RTx-015 in Retinitis Pigmentosa
BERKELEY, Calif.--(BUSINESS WIRE)--Ray Therapeutics (RayTx), a clinical-stage biopharmaceutical company pioneering optogenetic therapies for those living with retinal degenerative diseases, today anno...
Ray Therapeutics Awarded $8M CIRM Grant to Advance RTx-015 Gene Therapy for Retinitis Pigmentosa
BERKELEY, Calif.--(BUSINESS WIRE)--Ray Therapeutics Awarded $8M CIRM Grant to Advance RTx-015 Gene Therapy for Retinitis Pigmentosa.
Adverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsid
Adverum has granted Ray Therapeutics a non-exclusive, royalty-bearing license for the use of Adverum's proprietary intravitreal AAV.7m8 vector capsid together with RayTx's RTx-015 asset Adverum has gr...